内容概要：人工硬脑膜是用生物材料制成人体脑膜的替代物，用于因颅脑、脊髓损伤、肿瘤及其他颅脑 疾病引起的硬脑膜或脊膜缺损的修补，防止脑脊液外漏、颅内感染、脑膨出、脑粘连和疤痕等严重并发 症，以恢复其完整性。人工硬脑膜属于植介入耗材，伴随着国民可支配收入增加、老龄化程度加深，脑 血管疾病发病率上升，神经外科介入类手术需求增加，推动人工硬脑膜的需求放量增长。但2021年以来 随着集采的稳步推进，国内人工硬脑膜产品价格下降较为明显。2024年，我国人工硬脑膜需求量从2017 年的44.63万片增长至94.61万片，产品价格从2017年的1775元/片下降至800元/片，人工硬脑膜市场规模 则从2020年的10.26亿元下降至2024年的7.57亿元。 关键词：人工硬脑膜行业政策、人工硬脑膜产业链、人工硬脑膜需求量、人工硬脑膜行业均价、人工硬 脑膜市场规模、人工硬脑膜市场竞争格局、人工硬脑膜行业发展趋势 一、人工硬脑膜行业基本概况 神经外科作为医学领域最为复杂的学科之一，是以手术为主要手段，医治中枢神经系统（脑、脊髓）、 周围神经系统和植物神经系统疾病的一门临床外科专科。作为高精尖的前沿学科之一，神经外科对应用 在手术 ...

上海君澜律师事务所 关于北京佰仁医疗科技股份有限公司 2025 年第一次临时股东大会的法律意见书 致：北京佰仁医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）等法 律、法规、规章、规范性文件及《北京佰仁医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，上海君澜律师事务所（以下简称"本所"）接 受北京佰仁医疗科技股份有限公司（以下简称"公司"）的委托，指派本所律师 出席公司2025年第一次临时股东大会（以下简称"本次股东大会"），并就本次 股东大会的召集、召开程序及表决程序、表决结果等事项出具本法律意见书。 本法律意见书仅供本次股东大会之目的使用。本所律师同意将本法律意见书 随公司本次股东大会其他信息披露资料一并公告。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本 次股东大会所涉及的有关事项和相关文件进行了必要的核查和验证，现出具法律 意见如下： 公司董事会于 2025 年 8 月 28 日在《中国证券报》《上海证券报》《证券 时报》《证券日报》以及上海证券交易所网站（ ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-032 北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 16 日 （二） 股东大会召开的地点：北京市昌平区科技园东区华昌路 2 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人，其中，董事金磊先生、李武平先生、周正先生、 刘浩先生、曹贤智先生因工作原因线上参会； 2、 公司在任监事3人，出席3人； 3、 公司董事会秘书官小舟女士因工作原因线上出席了本次会议；其他高级管理 人员列席了本次会议。 | 1、出席会议的股东和代理人人数 | 40 | | --- | --- | | 普通股股东人数 | 40 | | 2、出席会议的股东所持有的表决 ...

Market Overview - The Shanghai Composite Index closed at 3861.87 points, slightly above the annual line, with a change of 0.04% [1] - The total trading volume of A-shares reached 23670.69 billion yuan [1] Stocks Breaking Annual Line - A total of 79 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Longxin Zhongke: 13.82% deviation, closing price at 149.59 yuan, with a daily increase of 14.89% and turnover rate of 5.54% [1] - Huazhi Wine: 10.72% deviation, closing price at 19.51 yuan, with a daily increase of 11.17% and turnover rate of 4.82% [1] - Hanbang High-tech: 8.19% deviation, closing price at 8.30 yuan, with a daily increase of 11.41% and turnover rate of 14.00% [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Huashu Holdings: 4.70% deviation, closing price at 2.62 yuan, with a daily increase of 5.65% [1] - Guoyao Modern: 2.60% deviation, closing price at 9.62 yuan, with a daily increase of 5.48% [1] - Ningxia Building Materials: just above the annual line with minor deviation [1]

北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会会议资料 证券代码：688198 证券简称：佰仁医疗 北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会会议资料 2025 年 9 月 | 2025年第一次临时股东大会会议须知 3 | | --- | | 2025年第一次临时股东大会会议议程 6 | | 2025年第一次临时股东大会会议议案 8 | | 议案一：关于取消公司监事会的议案 8 | | 议案二：关于变更公司注册资本、修订《公司章程》并办理工商变更登记的议案 9 | | 议案三：关于修订《公司股东会议事规则》的议案 11 | | 议案四：关于修订《公司董事会议事规则》的议案 12 | | 议案五：关于修订《公司独立董事工作制度》的议案 13 | | 议案六：关于修订《公司对外担保管理制度》的议案 14 | | 议案七：关于修订《公司关联交易管理制度》的议案 15 | | 议案八：关于修订《公司利润分配管理制度》的议案 16 | | 议案九：关于修订《公司重大经营与投资决策管理制度》的议案 17 | | 议案十：关于修订《公司累积投票制实施细则》的议案 18 | | 议案十一：关于修订 ...

北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会会议资 证券代码：688198 证券简称：佰仁医疗 北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会会议资料 2025 年 9 月 料 | 2025年第一次临时股东大会会议须知 | 3 | | --- | --- | | 2025年第一次临时股东大会会议议程 | 6 | | 2025年第一次临时股东大会会议议案 | 8 | | 议案一：关于取消公司监事会的议案 | 8 | | 议案二：关于变更公司注册资本、修订《公司章程》并办理工商变更登记的议案 | 9 | | 议案三：关于修订《公司股东会议事规则》的议案 | 11 | | 议案四：关于修订《公司董事会议事规则》的议案 | 12 | | 议案五：关于修订《公司独立董事工作制度》的议案 | 13 | | 议案六：关于修订《公司对外担保管理制度》的议案 | 14 | | 议案七：关于修订《公司关联交易管理制度》的议案 | 15 | | 议案八：关于修订《公司利润分配管理制度》的议案 | 16 | | 议案九：关于修订《公司重大经营与投资决策管理制度》的议案 | 17 | | 议案十：关于修订《公 ...

谈及后续有望在今年注册的产品，管理层表示，按今年已提交注册的产品时间顺序,分别为"眼科生物补 片"、"胶原纤维填充剂-I"、"复杂先心带瓣补片"、"ePTFE心包膜"、"介入肺动脉瓣及输送系统"、"消化 外科生物补片"、"卵圆孔未闭封堵器"和"胶原纤维填充剂-II",未来四个月,计划还有4款在研产品提交注 册 。 按目前注册审批进度，其中ePTFE心包膜和胶原纤维填充剂-I将在四季度有望获批，其它产品将陆续于 年底或明年第一季度和第二季度获批上市。 对于海外市场，管理层介绍，印尼海外注册已有16个产品，包括：动脉导管未闭封堵器，心血管病封堵 器输送系统，胸外科生物补片，涤纶补片，房缺封堵器，肺动脉带瓣管道，室间隔缺损封堵器，流出道 单瓣补片，心外科生物补片，三尖瓣成形环，限位可扩张人工生物心脏瓣膜，二尖瓣成形环，心脏瓣膜 生物补片，测瓣器，测环器，经导管主动脉瓣系统。市场拓展和新加坡筹备正在进行中。 还有投资者询问血管生物补片的市场前景。对此，管理层分析，公司血管生物补片主要为填补国内空 白，即因无可用产品一直未能开展的颈动脉斑块切除与血管重建术，因该手术可有效防止缺血性脑卒中 的发生。 根据王陇德院士团队有 ...

Core Viewpoint - The company reported strong financial performance in H1 2025, with significant revenue and profit growth, driven by successful product launches and effective cost management [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 248 million yuan, a year-on-year increase of 30.07% [1] - The net profit attributable to shareholders reached 71 million yuan, reflecting a substantial year-on-year growth of 102.90% [2] - Q2 2025 saw revenue of 148 million yuan, up 29.25% year-on-year and 47.68% quarter-on-quarter [1] - Q2 2025 net profit was 39 million yuan, a year-on-year increase of 44.75% and a quarter-on-quarter increase of 19.67% [1] Gross Margin and Cost Management - The company's gross margin for H1 2025 was 88.71%, a slight decrease of 0.82 percentage points year-on-year [1] - Q2 2025 gross margin improved to 90.54%, an increase of 1.07 percentage points year-on-year and 4.54 percentage points quarter-on-quarter [1] - The company effectively controlled costs through digitalization and strong cost management, contributing to improved gross margins [1] R&D and Product Development - The company maintained high R&D investment, with R&D expense ratio decreasing significantly due to revenue growth [2] - As of H1 2025, the company had 22 approved Class III medical devices, with 11 filling domestic market gaps [3] - 12 additional Class III medical device registration applications are expected in 2025, indicating a robust product pipeline [3] Market Position and Product Launches - The heart valve segment saw an 88.96% year-on-year increase in sales, with the TAVR product gaining significant market share [2] - The company received registration approval for TAVR in Indonesia and patent authorization in Japan [2] - The company is set to commercialize its unique "valve-in-valve" product in Q3 2025, which is expected to boost sales [4] Future Outlook - Revenue projections for 2025-2027 are set at 698 million, 1.015 billion, and 1.349 billion yuan, respectively, with net profits of 245 million, 406 million, and 555 million yuan [5] - The company is expected to benefit from increasing heart disease prevalence and expanding TAVR indications to lower-risk groups [5]

Group 1 - Bairun Medical (688198.SH) reported its semi-annual results for 2025, with 27 institutional investors holding a total of 28.2281 million A-shares, representing 20.55% of the total share capital [1] - The top ten institutional investors collectively hold 19.24% of the shares, with a decrease of 0.71 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, China Europe Times Pioneer Stock A, increased its holdings, while two funds, China Europe Value Selection Mixed A and China Europe Emerging Value One-Year Holding Mixed A, reduced their holdings by 0.96% [2] - Six new public funds were disclosed this period, including Medical Device ETF and Rongtong New Growth Mixed A [2] - One insurance fund, Ruizhong Life Insurance Co., Ltd. - Own Funds, increased its holdings slightly [2]

Group 1: Company Performance - XINWANDA reported a revenue of 26.985 billion yuan, a year-on-year increase of 12.82%, and a net profit of 856 million yuan, up 3.88% [1] - GUANGXUN TECHNOLOGY achieved a revenue of 5.243 billion yuan, a year-on-year increase of 68.59%, and a net profit of 372 million yuan, up 78.98% [1] - NORTHEAST SECURITIES posted a revenue of 2.046 billion yuan, a year-on-year increase of 31.66%, and a net profit of 431 million yuan, up 225.90% [1][2] - SHANXI COAL reported a revenue of 18.053 billion yuan, a year-on-year decrease of 16.30%, and a net profit of 1.014 billion yuan, down 48.44% [3] - SHENGTIAN NETWORK achieved a revenue of 633 million yuan, a year-on-year increase of 17.23%, and a net profit of 52.304 million yuan, up 1186.02% [4] - SANLIAN FORGING reported a revenue of 775 million yuan, a year-on-year increase of 6.86%, and a net profit of 71.335 million yuan, up 3.88% [5][6] - JIAMEI PACKAGING posted a revenue of 1.257 billion yuan, a year-on-year decrease of 8.73%, and a net profit of 19.7416 million yuan, down 65.59% [8] - ANZHENG FASHION achieved a revenue of 1.146 billion yuan, a year-on-year increase of 12.38%, and a net profit of 22.0834 million yuan, turning from a loss of 12.1096 million yuan in the previous year [9] - HUAHENG BIO reported a revenue of 1.489 billion yuan, a year-on-year increase of 46.54%, and a net profit of 115 million yuan, down 23.26% [10] - BAIREN MEDICAL achieved a revenue of 248 million yuan, a year-on-year increase of 30.07%, and a net profit of 71.4006 million yuan, up 102.90% [12] - TIANZHIHANG reported a revenue of 125 million yuan, a year-on-year increase of 114.89%, but a net loss of 57.5482 million yuan, worsening by 23.80% [14] - AIBO MEDICAL achieved a revenue of 787 million yuan, a year-on-year increase of 14.72%, and a net profit of 213 million yuan, up 2.53% [15] - ZHONGSHAN SHIPPING reported a revenue of 12.585 billion yuan, a year-on-year decrease of 4.91%, and a net profit of 2.125 billion yuan, down 14.91% [16] - SHANGHAI XINYANG achieved a revenue of 897 million yuan, a year-on-year increase of 35.67%, and a net profit of 133 million yuan, up 126.31% [17] - SHANCOAL INTERNATIONAL reported a revenue of 9.66 billion yuan, a year-on-year decrease of 31.28%, and a net profit of 655 million yuan, down 49.25% [18] - GUIDANCE reported a revenue of 935 million yuan, a year-on-year increase of 71.55%, and a net profit of 143 million yuan, turning from a loss of 48.9539 million yuan in the previous year [19] - YINGFANGWEI reported a revenue of 1.927 billion yuan, a year-on-year increase of 4.48%, but a net loss of 32.2966 million yuan, worsening from a loss of 22.4024 million yuan in the previous year [21] - CHINA COMMUNICATIONS reported a revenue of 14.665 billion yuan, a year-on-year increase of 2.91%, and a net profit of 1.621 billion yuan, up 1.34% [22] - CHINA GENERAL NUCLEAR reported a revenue of 39.167 billion yuan, a year-on-year decrease of 0.53%, and a net profit of 5.951 billion yuan, down 16.30% [23] - CHINA HEAVY TRUCK reported a revenue of 26.162 billion yuan, a year-on-year increase of 7.22%, and a net profit of 669 million yuan, up 8.10% [24] - SHENGGUANG GROUP achieved a revenue of 9.275 billion yuan, a year-on-year increase of 22.78%, and a net profit of 60.8446 million yuan, up 3.06% [25] Group 2: Dividend Proposals - XINWANDA proposed a cash dividend of 0.6 yuan per 10 shares [1] - SHANXI COAL proposed a cash dividend of 0.36 yuan per 10 shares [3] - ZHONGSHAN SHIPPING proposed a cash dividend of 0.7 yuan per 10 shares [16] - CHINA HEAVY TRUCK proposed a cash dividend of 3.15 yuan per 10 shares [24]